TSNLF Quote, Financials, Valuation and Earnings

Autolus Therapeutics PLC has a net margin of -- compared to Tristel PLC's net margin of -522.15%. Tristel PLC's return on equity of 20.43% beat Autolus Therapeutics PLC's return on equity of -80.74%.

Tristel PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.45 which suggests that it could grow by 301.92%. Given that Autolus Therapeutics PLC has higher upside potential than Tristel PLC, analysts believe Autolus Therapeutics PLC is more attractive than Tristel PLC.

Tristel PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.049, suggesting its more volatile than the S&P 500 by 104.921%.

Tristel PLC has a quarterly dividend of $0.11 per share corresponding to a yield of 3.26%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tristel PLC pays 95.92% of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend. Tristel PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Tristel PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $10.1M. Tristel PLC's net income of -- is lower than Autolus Therapeutics PLC's net income of -$82.1M. Notably, Tristel PLC's price-to-earnings ratio is 31.31x while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tristel PLC is 4.85x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of -- compared to Tristel PLC's net margin of --. Tristel PLC's return on equity of 20.43% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Tristel PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 303.85%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Tristel PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Tristel PLC.

Tristel PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.046%.

Tristel PLC has a quarterly dividend of $0.11 per share corresponding to a yield of 3.26%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tristel PLC pays 95.92% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. Tristel PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Tristel PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Tristel PLC's net income of -- is lower than Biodexa Pharmaceuticals PLC's net income of --. Notably, Tristel PLC's price-to-earnings ratio is 31.31x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tristel PLC is 4.85x versus 4.01x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of -- compared to Tristel PLC's net margin of --. Tristel PLC's return on equity of 20.43% beat NuCana PLC's return on equity of --.

Tristel PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 4978.74%. Given that NuCana PLC has higher upside potential than Tristel PLC, analysts believe NuCana PLC is more attractive than Tristel PLC.

Tristel PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.67%.

Tristel PLC has a quarterly dividend of $0.11 per share corresponding to a yield of 3.26%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tristel PLC pays 95.92% of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend. Tristel PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Tristel PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Tristel PLC's net income of -- is lower than NuCana PLC's net income of -$5.9M. Notably, Tristel PLC's price-to-earnings ratio is 31.31x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tristel PLC is 4.85x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

Verona Pharma PLC has a net margin of -- compared to Tristel PLC's net margin of -763.91%. Tristel PLC's return on equity of 20.43% beat Verona Pharma PLC's return on equity of -74.15%.

Tristel PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Verona Pharma PLC has an analysts' consensus of $47.29 which suggests that it could grow by 5.53%. Given that Verona Pharma PLC has higher upside potential than Tristel PLC, analysts believe Verona Pharma PLC is more attractive than Tristel PLC.

Tristel PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.400, suggesting its less volatile than the S&P 500 by 60.012%.

Tristel PLC has a quarterly dividend of $0.11 per share corresponding to a yield of 3.26%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tristel PLC pays 95.92% of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend. Tristel PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Tristel PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $5.6M. Tristel PLC's net income of -- is lower than Verona Pharma PLC's net income of -$43M. Notably, Tristel PLC's price-to-earnings ratio is 31.31x while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tristel PLC is 4.85x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.